Latest filings (excl ownership)
15-12G
Securities registration termination
13 Jan 23
8-K/A
Termination of a Material Definitive Agreement
13 Jan 23
EFFECT
Notice of effectiveness
6 Jan 23
25-NSE
Exchange delisting
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
POS AM
Prospectus update (post-effective amendment)
3 Jan 23
8-K
Termination of a Material Definitive Agreement
3 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
3 Jan 23
SC TO-T/A
Third party tender offer statement (amended)
3 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
23 Dec 22
SC 14D9
Tender offer solicitation
22 Dec 22
SC TO-T/A
Third party tender offer statement (amended)
9 Dec 22
SC 14D9/A
Tender offer solicitation (amended)
9 Dec 22
SC 14D9
Tender offer solicitation
1 Dec 22
SC TO-T
Third party tender offer statement
1 Dec 22
SC14D9C
Written communication relating to third party tender offer
16 Nov 22
SC TO-C
Information about tender offer
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
10 Nov 22
SC14D9C
Written communication relating to third party tender offer
8 Nov 22
8-K
Entry into a Material Definitive Agreement
8 Nov 22
SC TO-C
Information about tender offer
8 Nov 22
SC TO-C
Information about tender offer
7 Nov 22
SC14D9C
Written communication relating to third party tender offer
7 Nov 22
SC14D9C
Written communication relating to third party tender offer
7 Nov 22
8-K
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
7 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
11 Aug 22
8-K
Departure of Directors or Certain Officers
12 Jul 22
8-K
Oyster Point Pharma Announces Operating Expense Streamlining Plan
28 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 22
DEFA14A
Additional proxy soliciting materials
17 May 22
8-K
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights
5 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
DEF 14A
Definitive proxy
22 Apr 22
8-K
Oyster Point Pharma Announces Retirement of William J. Link from Board of Directors
18 Mar 22
10-K
2021 FY
Annual report
24 Feb 22
Latest ownership filings
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13D/A
Versant Venture Capital VI, L.P.
13 Jan 23
SC 13D/A
New Enterprise Associates 14, L.P.
9 Jan 23
SC 13D/A
InvOpps IV US, L.P.
5 Jan 23
4
SACHA LAINOVIC
5 Jan 23
4
Change in insider ownership
4 Jan 23
4
Ali Behbahani
4 Jan 23
4
PATRICK J KERINS
4 Jan 23
4
AIMEE S WEISNER
4 Jan 23
4
Benjamin Tsai
4 Jan 23
4
Donald J Santel
4 Jan 23
4
Clare Ozawa
4 Jan 23
4
Jeffrey Nau
4 Jan 23
4
Mark Anthony Murray
4 Jan 23
4
Daniel Lochner
4 Jan 23
4
George Christopher Eliades
4 Jan 23
4
MICHAEL G ATIEH
4 Jan 23
SC 13D/A
InvOpps IV US, L.P.
21 Dec 22
4/A
Jeffrey Nau
6 Dec 22
4
Daniel Lochner
6 Dec 22
4
Jeffrey Nau
5 Dec 22
SC 13D/A
New Enterprise Associates 14, L.P.
21 Nov 22
SC 13G
Paradigm Biocapital Advisors LP
18 Jul 22
4
Daniel Lochner
8 Jul 22
4
Jeffrey Nau
8 Jul 22
4
Ali Behbahani
8 Jun 22
4
Clare Ozawa
8 Jun 22
4
George Christopher Eliades
8 Jun 22
4
AIMEE S WEISNER
8 Jun 22
4
Benjamin Tsai
8 Jun 22
4
Mark Anthony Murray
8 Jun 22
4
MICHAEL G ATIEH
8 Jun 22
4
Donald J Santel
8 Jun 22
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 22
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13D/A
Versant Venture Capital VI, L.P.
13 Jan 22
4
John Snisarenko
11 Jan 22